Sartorius Stedim Biotech S.A.
Sartorius Stedim Biotech S.A. Fundamental Analysis
Sartorius Stedim Biotech S.A. (SRTOY) shows weak financial fundamentals with a PE ratio of 602.66, profit margin of 8.62%, and ROE of 6.33%. The company generates $3.0B in annual revenue with weak year-over-year growth of 0.16%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 31.4/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze SRTOY's fundamental strength across five key dimensions:
Efficiency Score
WeakSRTOY struggles to generate sufficient returns from assets.
Valuation Score
ModerateSRTOY shows balanced valuation metrics.
Growth Score
WeakSRTOY faces weak or negative growth trends.
Financial Health Score
ExcellentSRTOY maintains a strong and stable balance sheet.
Profitability Score
WeakSRTOY struggles to sustain strong margins.
Key Financial Metrics
Is SRTOY Expensive or Cheap?
P/E Ratio
SRTOY trades at 602.66 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, SRTOY's PEG of -33.80 indicates potential undervaluation.
Price to Book
The market values Sartorius Stedim Biotech S.A. at 37.60 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 106.11 times EBITDA. This signals the market has high growth expectations.
How Well Does SRTOY Make Money?
Net Profit Margin
For every $100 in sales, Sartorius Stedim Biotech S.A. keeps $8.62 as profit after all expenses.
Operating Margin
Core operations generate 17.70 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $6.33 in profit for every $100 of shareholder equity.
ROA
Sartorius Stedim Biotech S.A. generates $3.18 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Sartorius Stedim Biotech S.A. produces operating cash flow of $550.99M, showing steady but balanced cash generation.
Free Cash Flow
Sartorius Stedim Biotech S.A. produces free cash flow of $157.56M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.02 in free cash annually.
FCF Yield
SRTOY converts 0.10% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
602.66
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-33.80
vs 25 benchmark
P/B Ratio
Price to book value ratio
37.60
vs 25 benchmark
P/S Ratio
Price to sales ratio
52.42
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.67
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.02
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.06
vs 25 benchmark
ROA
Return on assets percentage
0.03
vs 25 benchmark
ROCE
Return on capital employed
0.08
vs 25 benchmark
How SRTOY Stacks Against Its Sector Peers
| Metric | SRTOY Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 602.66 | 28.25 | Worse (Expensive) |
| ROE | 6.33% | 780.00% | Weak |
| Net Margin | 8.62% | -20122.00% (disorted) | Weak |
| Debt/Equity | 0.67 | 0.30 | Weak (High Leverage) |
| Current Ratio | 1.02 | 4.66 | Neutral |
| ROA | 3.18% | -14687.00% (disorted) | Weak |
SRTOY outperforms its industry in 0 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Sartorius Stedim Biotech S.A.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
83.81%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
-28.90%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
150.33%
Industry Style: Defensive, Growth, Innovation
High Growth